{"version":"market-claims.v1","claim":{"id":"mcl_f1f9020f53bfc282c6","url":"/trace/claims/mcl_f1f9020f53bfc282c6","status":"PUBLISHED","claimType":"DIRECTIONAL_THESIS","direction":"LONG","claimText":"Lilly just got a real oral weight-loss pill approved while copycats sell an oral version with zero human studies and a RICO lawsuit hanging over it.","confidence":0.72,"expert":{"slug":"tbpn","displayName":"TBPN","kind":"PERSON","status":"UNCLAIMED","avatarUrl":"/api/avatars/f01e70d9-d","url":"/trace/experts/tbpn","claimed":false},"primaryEntity":{"kind":"ASSET","assetClass":"EQUITY","symbol":"LLY","name":"LLY","exchange":null,"confidence":0.78},"evidence":{"evidenceUrl":"https://www.youtube.com/watch?v=wrnhYB2uIA8&t=6072s","sourceUrl":"https://youtube.com/watch?v=wrnhYB2uIA8","timecode":"101:12","startMs":6072000,"endMs":null,"excerpt":"The day before this article ran, the day before, Lilly's oral got approved. It was not tirzepatide. In fact, it wasn't even a peptide."},"performance":{"entryPrice":925.29,"currentPrice":null,"returnPct":null,"relativePct":null,"method":"PASTE_AUTHOR_PRICE"},"resolutionStatus":"OPEN","ambiguityNotes":null,"horizon":"multi-year","isExplicitTrade":false,"notFinancialAdvice":true,"disclaimer":"AISO tracks public statements, not verified portfolio positions. This is not financial advice."},"expert":{"slug":"tbpn","displayName":"TBPN","kind":"PERSON","status":"UNCLAIMED","avatarUrl":"/api/avatars/f01e70d9-d","url":"/trace/experts/tbpn","claimed":false},"source":{"platform":"YOUTUBE","title":"We're Back! $1B GLP-1 Lessons. AI Funding Debates. China's 2030 Master Plan.","sourceUrl":"https://youtube.com/watch?v=wrnhYB2uIA8","publishedAt":"2026-04-06T19:37:41.000Z"},"evidence":{"evidenceUrl":"https://www.youtube.com/watch?v=wrnhYB2uIA8&t=6072s","sourceUrl":"https://youtube.com/watch?v=wrnhYB2uIA8","timecode":"101:12","startMs":6072000,"endMs":null,"excerpt":"The day before this article ran, the day before, Lilly's oral got approved. It was not tirzepatide. In fact, it wasn't even a peptide.","quote":"The day before this article ran, the day before, Lilly's oral got approved. It was not tirzepatide. In fact, it wasn't even a peptide.","speaker":"Jonathan Slotkin"},"entities":[{"kind":"ASSET","assetClass":"EQUITY","symbol":"LLY","name":"LLY","exchange":null,"confidence":0.78}],"marketData":{"entry":{"price":925.29,"currency":"USD","observedAt":"2026-04-06T19:37:41.000Z","method":"PASTE_AUTHOR_PRICE"},"current":null,"returnPct":null},"snapshots":[{"kind":"ENTRY","symbol":"LLY","assetClass":"EQUITY","price":925.29,"probability":null,"currency":"USD","provider":"paste.trade","providerSymbol":"xyz:LLY","observedAt":"2026-04-06T19:37:41.000Z","method":"PASTE_AUTHOR_PRICE","returnPct":null,"relativePct":null}]}